Alpha versus beta: Are we on the way to resolve the mystery as to which is the endogenous ligand for natural killer T cells?

Clinical and Experimental Immunology

Volumn 158, Issue 3, 2009, Pages 300-307

  Ilan, Y ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Alpha galactosylceramide; Beta glucosylceramide; CD1d; Gaucher disease; Glycosphingolipids; NKT cells

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; GLUCOSYLCERAMIDASE; GLYCOSPHINGOLIPID; LIGAND;

ARTICLE; BACTERIUM; ENZYME REPLACEMENT; HUMAN; IMMUNE MEDIATED INJURY; IMMUNE SYSTEM; IMMUNOMODULATION; INFECTION; MAMMAL; NATURAL KILLER T CELL; NONHUMAN; PLASTICITY; PRIORITY JOURNAL; PROTOZOON; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD1D; GLYCOSPHINGOLIPIDS; HUMANS; LIGANDS; LYMPHOCYTE ACTIVATION; NATURAL KILLER T-CELLS;

EID: 70350585024     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.04030.x     Document Type: Article

References (100)

1. Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 2004 114 : 1379 1388.
2. Godfrey DI, Berzins SP. Control points in NKT-cell development. Nat Rev Immunol 2007 7 : 505 518.
3. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007 25 : 297 336.
4. Kronenberg M, Engel I. On the road: progress in finding the unique pathway of invariant NKT cell differentiation. Curr Opin Immunol 2007 19 : 186 193.
5. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004 4 : 231 237.
6. Stronge VS, Salio M, Jones EY, Cerundolo V. A closer look at CD1d molecules: new horizons in studying NKT cells. Trends Immunol 2007 28 : 455 462.
7. Nowak M, Stein-Streilein J. Invariant NKT cells and tolerance. Int Rev Immunol 2007 26 : 95 119.
8. Menachem Y, Trop S, Kolker O et al. Adoptive transfer of NK 1·1+ lymphocytes in immune-mediated colitis: a pro-inflammatory or a tolerizing subgroup of cells? Microbes Infect 2005 7 : 825 835.
9. Shibolet O, Alper R, Zlotogarov L et al. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells. Int J Cancer 2003 106 : 236 243.
10. Shibolet O, Alper R, Zolotarov L et al. The role of intrahepatic CD8+ T cell trapping and NK1·1+ cells in liver-mediated immune regulation. Clin Immunol 2004 111 : 82 92.
11. Dougan SK, Kaser A, Blumberg RS. CD1 expression on antigen-presenting cells. Curr Top Microbiol Immunol 2007 314 : 113 141.
12. Crowe NY, Uldrich AP, Kyparissoudis K et al. Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol 2003 171 : 4020 4027.
13. Brutkiewicz RR. CD1d ligands: the good, the bad, and the ugly. J Immunol 2006 177 : 769 775.
14. Brutkiewicz RR, Lin Y, Cho S, Hwang YK, Sriram V, Roberts TJ. CD1d-mediated antigen presentation to natural killer T (NKT) cells. Crit Rev Immunol 2003 23 : 403 419.
15. Van Kaer L. NKT cells: T lymphocytes with innate effector functions. Curr Opin Immunol 2007 19 : 354 364.
16. Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu Rev Immunol 2004 22 : 817 890.
17. Bendelac A, Teyton L, Savage PB. Lipid presentation by CD1: the short and the long lipid story. Nat Immunol 2002 3 : 421 422.
18. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today 2000 21 : 573 583.
19. Lalioui L, Pellegrini E, Dramsi S et al. The SrtA sortase of Streptococcus agalactiae is required for cell wall anchoring of proteins containing the LPXTG motif, for adhesion to epithelial cells, and for colonization of the mouse intestine. Infect Immun 2005 73 : 3342 3350.
20. Gadola SD, Koch M, Marles-Wright J et al. Structure and binding kinetics of three different human CD1d-alpha-galactosylceramide-specific T cell receptors. J Exp Med 2006 203 : 699 710.
21. Silk JD, Salio M, Brown J, Jones EY, Cerundolo V. Structural and functional aspects of lipid binding by CD1 molecules. Annu Rev Cell Dev Biol 2008 24 : 369 395.
22. Matsuda JL, Mallevaey T, Scott-Browne J, Gapin L. CD1d-restricted iNKT cells, the 'Swiss-Army knife' of the immune system. Curr Opin Immunol 2008 20 : 358 368.
23. Rothenberg EV. Negotiation of the T lineage fate decision by transcription-factor interplay and microenvironmental signals. Immunity 2007 26 : 690 702.
24. Cerundolo V, Silk JD, Masri SH, Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 2009 9 : 28 38.
25. Fujii S, Shimizu K, Hemmi H, Steinman RM. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity. Immunol Rev 2007 220 : 183 198.
26. Morel PA, Feili-Hariri M, Coates PT, Thomson AW. Dendritic cells, T cell tolerance and therapy of adverse immune reactions. Clin Exp Immunol 2003 133 : 1 10.
27. Ilan Y, Ohana M, Pappo O et al. Alleviation of acute and chronic graft-versus-host disease in a murine model is associated with glucocerebroside-enhanced natural killer T lymphocyte plasticity. Transplantation 2007 83 : 458 467.
28. Rothenberg EV, Dionne CJ. Lineage plasticity and commitment in T-cell development. Immunol Rev 2002 187 : 96 115.
29. Lalazar G, Ben Ya'acov A, Lador A et al. Modulation of intracellular machinery by beta-glycolipids is associated with alteration of NKT lipid rafts and amelioration of concanavalin-induced hepatitis. Mol Immunol 2008 45 : 3517 3525.
30. Lencer WI, Delp C, Neutra MR, Madara JL. Mechanism of cholera toxin action on a polarized human intestinal epithelial cell line: role of vesicular traffic. J. Cell Biol 1992 117 : 1197 1209.
31. Berzofsky JA, Terabe M. NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J Immunol 2008 180 : 3627 3635.
32. Lalazar G, Preston S, Zigmond E, Ben Yaacov A, Ilan Y. Glycolipids as immune modulatory tools. Mini Rev Med Chem 2006 6 : 1249 1253.
33. Kronenberg M. Interview: glycolipid antigen presentation by CD1d and the therapeutic potential of NKT cell activation. J Vis Exp 2007 635.
34. Speak AO, Cerundolo V, Platt FM. CD1d presentation of glycolipids. Immunol Cell Biol 2008 86 : 588 597.
35. Tsuji M, Suzuki K, Kinoshita K, Fagarasan S. Dynamic interactions between bacteria and immune cells leading to intestinal IgA synthesis. Semin Immunol 2008 20 : 59 66.
36. Sriram V, Du W, Gervay-Hague J, Brutkiewicz RR. Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. Eur J Immunol 2005 35 : 1692 1701.
37. Van Kaer L. Alpha-galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat Rev Immunol 2005 5 : 31 42.
38. Miyake S, Yamamura T. Therapeutic potential of glycolipid ligands for natural killer (NK) T cells in the suppression of autoimmune diseases. Curr Drug Targets Immune Endocr Metabol Disord 2005 5 : 315 322.
39. Yamamura T, Miyamoto K, Illes Z, Pal E, Araki M, Miyake S. NKT cell-stimulating synthetic glycolipids as potential therapeutics for autoimmune disease. Curr Top Med Chem 2004 4 : 561 567.
40. Wu L, Van Kaer L. Natural killer T cells and autoimmune disease. Curr Mol Med 2009 9 : 4 14.
41. Osman Y, Kawamura T, Naito T et al. Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide. Eur J Immunol 2000 30 : 1919 1928.
42. Bittman R. The 2003 ASBMB-Avanti Award in Lipids address: applications of novel synthetic lipids to biological problems. Chem Phys Lipids 2004 129 : 111 131.
43. Yu KO, Im JS, Molano A et al. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. Proc Natl Acad Sci USA 2005 102 : 3383 3388.
44. Gonzalez-Aseguinolaza G, de Oliveira C, Tomaska M et al. Alpha-galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria. Proc Natl Acad Sci USA 2000 97 : 8461 8466.
45. Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC et al. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 2002 195 : 617 624.
46. Chang YJ, Huang JR, Tsai YC et al. Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids. Proc Natl Acad Sci USA 2007 104 : 10299 10304.
47. Skold M, Behar SM. Role of CD1d-restricted NKT cells in microbial immunity. Infect Immun 2003 71 : 5447 5455.
48. Singh RD, Puri V, Valiyaveettil JT, Marks DL, Bittman R, Pagano RE. Selective caveolin-1-dependent endocytosis of glycosphingolipids. Mol Biol Cell 2003 14 : 3254 3265.
49. Zajonc DM, Cantu C 3rd., Mattner J et al. Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. Nat Immunol 2005 6 : 810 818.
50. Stanic AK, Park JJ, Joyce S. Innate self recognition by an invariant, rearranged T-cell receptor and its immune consequences. Immunology 2003 109 : 171 184.
51. Tupin E, Kinjo Y, Kronenberg M. The unique role of natural killer T cells in the response to microorganisms. Nat Rev Microbiol 2007 5 : 405 417.
52. Mougous JD, Cuff ME, Raunser S et al. Locus of Pseudomonas aeruginosa encodes a protein secretion apparatus. Science 2006 312 : 1526 1530.
53. Macpherson AJ, McCoy KD, Johansen FE, Brandtzaeg P. The immune geography of IgA induction and function. Mucosal Immunol 1 : 11 22.
54. Porubsky S, Speak AO, Luckow B, Cerundolo V, Platt FM, Grone HJ. Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc Natl Acad Sci USA 2007 104 : 5977 5982.
55. Zhou X, Gao DQ, Michalski J, Benitez JA, Kaper JB. Induction of Interleukin-8 in T84 Cells by Vibrio cholerae. Infect Immun 2004 72 : 389 397.
56. Kinjo Y, Kronenberg M. Valpha14i NKT cells are innate lymphocytes that participate in the immune response to diverse microbes. J Clin Immunol 2005 25 : 522 533.
57. Mattner J, Debord KL, Ismail N et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005 434 : 525 529.
58. De Silva AD, Park JJ, Matsuki N et al. Lipid protein interactions: the assembly of CD1d1 with cellular phospholipids occurs in the endoplasmic reticulum. J Immunol 2002 168 : 723 733.
59. Giabbai B, Sidobre S, Crispin MD et al. Crystal structure of mouse CD1d bound to the self ligand phosphatidylcholine: a molecular basis for NKT cell activation. J Immunol 2005 175 : 977 984.
60. Goni FM, Alonso A. Biophysics of sphingolipids I. Membrane properties of sphingosine, ceramides and other simple sphingolipids. Biochim Biophys Acta 2006 1758 : 1902 1921.
61. Sonnino S, Mauri L, Chigorno V, Prinetti A. Gangliosides as components of lipid membrane domains. Glycobiology 2007 17 : 1R 13R.
62. Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis 2002 6 : 727 737.
63. Apter FM, Lencer WI, Finkelstein RA, Mekalanos JJ, Neutra MR. Monoclonal immunoglobulin A antibodies directed against cholera toxin prevent the toxin-induced chloride secretory response and block toxin binding to epithelial cells in vitro. Infect Immun 1993 61 : 5271 5278.
64. Margalit MZL, Hemed N, Elstein D, Zimran A, Ilan Y. Glucocerebroside induces altered anti hepatitis C immunity in patients with Gaucher's disease. Hepatology 2003 38 (Suppl. 1 490A.
65. Baleria A. Impact of glycosphingolipid accumulation on the immunological phenotype: Gaucher disease as a model. 5th Interantional CD1d NKT meeting 2009. Abstract S3-8.
66. Margalit M, Ghazala SA, Alper R et al. Glucocerebroside treatment ameliorates ConA hepatitis by inhibition of NKT lymphocytes. Am J Physiol Gastrointest Liver Physiol 2005 289 : G917 25.
67. Ortaldo JR, Young HA, Winkler-Pickett RT, Bere EW Jr., Murphy WJ, Wiltrout RH. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides. J Immunol 2004 172 : 943 953.
68. Stanic AK, De Silva AD, Park JJ et al. Defective presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by beta-D-glucosylceramide synthase deficiency. Proc Natl Acad Sci USA 2003 100 : 1849 1854.
69. Ilan Y, Elstein D, Zimran A. Glucocerebroside: an evolutionary advantage for patients with Gaucher disease and a new immunomodulatory agent. Immunol Cell Biol 2009.
70. Zigmond E, Preston S, Pappo O et al. Beta-glucosylceramide: a novel method for enhancement of natural killer T lymphoycte plasticity in murine models of immune-mediated disorders. Gut 2007 56 : 82 9.
71. Safadi R, Zigmond E, Pappo O, Shalev Z, Ilan Y. Amelioration of hepatic fibrosis via beta-glucosylceramide-mediated immune modulation is associated with altered CD8 and NKT lymphocyte distribution. Int Immunol 2007 19 : 1021 1029.
72. Rosenau J, Hooman N, Rifai K et al. Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response. Transpl Int 2006 19 : 828 833.
73. Margalit M, Shalev Z, Pappo O et al. Glucocerebroside ameliorates the metabolic syndrome in OB/OB mice. J Pharmacol Exp Ther 2006 319 : 105 110.
74. Zigmond E, Zangen SW, Pappo O et al. beta}-Glycosphingolipids improve glucose intolerance and hepatic steatosis of the Cohen diabetic rat. Am J Physiol Endocrinol Metab 2009 296 : E72 8.
75. Tayer-Shiffman O ZE, Pappo O, Sklair-Levy M et al. Amelioration of hepatic steatosis and insulin resistance in psammomys obesus by a combination of beta-glycolipids is associated with STAT 1 and 4 expression. Hepatology 2006 44 (Suppl. 1 71A.
76. Mizrahi M, Lalazar G, Ben Ya'acov A et al. Beta-glycoglycosphingolipid- induced augmentation of the anti-HBV immune response is associated with altered CD8 and NKT lymphocyte distribution: a novel adjuvant for HBV vaccination. Vaccine 2008 26 : 2589 2595.
77. Onoe K, Yanagawa Y, Minami K, Iijima N, Iwabuchi K. Th1 or Th2 balance regulated by interaction between dendritic cells and NKT cells. Immunol Res 2007 38 : 319 332.
78. Yamamura T, Sakuishi K, Illes Z, Miyake S. Understanding the behavior of invariant NKT cells in autoimmune diseases. J Neuroimmunol 2007 191 : 8 15.
79. Lalazar G PS, Lador A, Pappo O, Zolotarov L, Ilan Y. Alleviation of ConA immune mediated hepatitis via glycolipids: the role of beta versus alpha configuration in determining NKT lymphocyte distribution and the TH1/TH2 paradigm. J Hepatol 2006 44 : S237.
80. Park YK, Lee JW, Ko YG, Hong S, Park SH. Lipid rafts are required for efficient signal transduction by CD1d. Biochem Biophys Res Commun 2005 327 : 1143 1154.
81. Sehgal PB. Plasma membrane rafts and chaperones in cytokine/STAT signaling. Acta Biochim Pol 2003 50 : 583 594.
82. Wieland CW, Florquin S, Maris NA et al. The MyD88-dependent, but not the MyD88-independent, pathway of TLR4 signaling is important in clearing nontypeable Haemophilus influenzae from the mouse lung. J Immunol 2005 175 : 6042 6049.
83. Butters TD, Dwek RA, Platt FM. New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases. Adv Exp Med Biol 2003 535 : 219 226.
84. Charrow J. Enzyme replacement therapy for Gaucher disease. Expert Opin Biol Ther 2009 9 : 121 131.
85. Cox TM, Aerts JM, Belmatoug N et al. Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J Inherit Metab Dis 2008 31 : 319 336.
86. Mehta A. Gaucher disease: unmet treatment needs. Acta Paediatr Suppl 2008 97 : 83 7.
87. Pastores GM, Weinreb NJ, Aerts H et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004 41 : 4 14.
88. Weinreb NJ, Deegan P, Kacena KA et al. Life expectancy in Gaucher disease type 1. Am J Hematol 2008 83 : 896 900.
89. Lee RE. The pathology of Gaucher disease. Prog Clin Biol Res 1982 95 : 177 217.
90. Zimran A, Ilan Y, Elstein D. Enzyme replacement therapy for mild patients with Gaucher disease. Am J Hematol 2009 84 : 202 204.
91. Langeveld M, de Fost M, Aerts JM, Sauerwein HP, Hollak CE. Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy. Blood Cell Mol Dis 2008 40 : 428 432.
92. Zigmond E, Papo O, Zangen S et al. Treatment of non-alcoholic steatohepatitis by B-glucosylceramide: a phase I/II clinical study. Hepatology 2006 44 : 180A.
93. Lalazar G, Ben Ya'acov A, Livovsky DM et al. Beta-glycoglycosphingolipid- induced alterations of the STAT signaling pathways are dependent on CD1d and the lipid raft protein flotillin-2. Am J Pathol 2009 174 : 1390 1399.
94. Halder G, Callaerts P, Gehring WJ. Induction of ectopic eyes by targeted expression of the eyeless gene in Drosophila. Science 1995 267 : 1788 1792.
95. Bijl N, Scheij S, Houten S, Boot RG, Groen AK, Aerts JM. The glucosylceramide synthase inhibitor N-(5-adamantane-1-yl-methoxy-pentyl)- deoxynojirimycin induces sterol regulatory element-binding protein-regulated gene expression and cholesterol synthesis in HepG2 cells. J Pharmacol Exp Ther 2008 326 : 849 855.
96. Bijl N, van Roomen CP, Triantis V et al. Reduction of glycosphingolipid biosynthesis stimulates biliary lipid secretion in mice. Hepatology 2009 49 : 637 645.
97. van Eijk M, Aten J, Bijl N et al. Reducing glycosphingolipid content in adipose tissue of obese mice restores insulin sensitivity, adipogenesis and reduces inflammation. PLoS One 2009 4 : e4723.
98. Zhao H, Przybylska M, Wu IH et al. Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes 2007 56 : 1210 1218.
99. Tagami S, Inokuchi Ji J, Kabayama K et al. Ganglioside GM3 participates in the pathological conditions of insulin resistance. J Biol Chem 2002 277 : 3085 3092.
100. Lalazar G, Ben Ya'acov A, Eliakim-Raz N et al. beta}-Glycosphingolipids- mediated lipid raft alteration is associated with redistribution of NKT cells and increased intrahepatic CD8+ T lymphocyte trapping. J Lipid Res 2008 49 : 1884 1893.